Avalyn Announces Additional Long-term Data on AP01, Inhaled Pirfenidone, for the Treatment of Pulmonary Fibrosis to be Presented at the European Alliance of Associations for Rheumatology 2026

Avalyn (Nasdaq: AVLN) announced an upcoming EULAR 2026 poster on AP01, inhaled pirfenidone, for progressive pulmonary fibrosis.

Rhea-AI Summary

Avalyn (Nasdaq: AVLN) announced an upcoming EULAR 2026 poster on AP01, inhaled pirfenidone, for progressive pulmonary fibrosis. Updated ATLAS open-label extension data will describe the long-term tolerability profile of AP01 at up to four years of treatment.

The poster, POS1150, will be presented June 6, 2026, in London and made available on Avalyn’s website.

Argus May 21 session

+1.36% close to close Open Argus

Details

News Market Reaction – AVLN

On May 21, the day this news came out, AVLN closed 1.36% above the previous close.

Data tracked by StockTitan Argus for the May 21 session.

Key Figures

Treatment duration: up to four years Conference dates: June 3-6, 2026 Poster session time: June 6, 10:15 BST +1 more

Treatment duration

up to four years

ATLAS open-label extension trial for AP01

Conference dates

June 3-6, 2026

EULAR 2026 in London

Poster session time

June 6, 10:15 BST

Poster View VIII at EULAR 2026

Poster ID

POS1150

EULAR 2026 poster on AP01 4-year data

Historical Context

3 past events · Latest: May 05

3 events

1. May 05

   Scientific conference update

   24h Move

   +1.0%

   Patient-centered AP01 research posters at ATS 2026 conference.

2. May 03

   Peer M&A, IPO mention

   24h Move

   -2.6%

   Article highlighting venture investors’ track record and Avalyn IPO inclusion.

3. May 01

   IPO completion

   24h Move

   -2.6%

   Closing of IPO and underwriters’ option, raising gross proceeds for Avalyn.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

open-label extension trial, progressive pulmonary fibrosis, nebulized pirfenidone, interstitial lung diseases, +1 more

5 terms

open-label extension trial medical

"Updated findings from the ATLAS open-label extension trial will highlight..."

An open-label extension trial is a follow-up study where participants who finished an earlier clinical trial keep taking the experimental treatment and both they and the researchers know what drug is being given. It lets companies collect longer-term safety and effectiveness information that shorter, blinded trials may not capture. For investors, results from these extensions are like getting additional product testing and user feedback over time, which can reduce uncertainty about future approval, market acceptance, and potential liabilities.

progressive pulmonary fibrosis medical

"...among the cohort of patients with progressive pulmonary fibrosis at up to..."

Progressive pulmonary fibrosis is a condition where lung tissue becomes increasingly scarred and stiff over time, reducing the lungs’ ability to move air and exchange oxygen—imagine a once-spongey lung turning into a hardened sponge that can’t expand. It matters to investors because a growing or underserved patient population, ongoing clinical trials, and potential new treatments or diagnostics can drive revenue, regulatory milestones, partnership activity, and share-price volatility in healthcare, biotech, and medical-device companies.

nebulized pirfenidone medical

"Title: Nebulized pirfenidone (AP01) for progressive pulmonary fibrosis..."

Nebulized pirfenidone is the antifibrotic medication pirfenidone reformulated so patients inhale it as a fine mist from a nebulizer, delivering the drug directly to the lungs instead of swallowing a pill. Investors care because inhaled delivery can concentrate treatment where lung scarring occurs, potentially improving effectiveness, lowering whole‑body side effects, and creating new market or regulatory opportunities—like spot‑treating a stain rather than soaking an entire garment.

interstitial lung diseases medical

"...other interstitial lung diseases: 4-year data from the ATLAS open label..."

A group of conditions that cause inflammation or scarring in the lung’s interstitium — the thin, sponge-like support tissue between air sacs — which makes the lungs stiffer and harder to move air. Investors should care because these diseases drive demand for diagnostics, drugs and medical devices, influence clinical-trial and regulatory risk for therapies, and can have substantial long-term healthcare costs that affect company revenue and valuations.

connective tissue disease-associated medical

"...pulmonary fibrosis in connective tissue disease-associated and other..."

Connective tissue disease-associated describes a symptom, condition, or medical finding that is linked to an underlying connective tissue disease — a group of immune-driven disorders that affect the body’s structural proteins (like collagen) and organs. For investors, this label narrows the relevant patient population and can change how a drug or test is developed, tested, approved and paid for, much like marketing a product specifically for customers with a particular chronic condition.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

BOSTON, May 21, 2026 (GLOBE NEWSWIRE) -- Avalyn Pharma Inc. (Nasdaq: AVLN), a clinical-stage biopharmaceutical company pioneering inhaled therapies to transform the treatment paradigm of serious, rare respiratory diseases, today announced an upcoming poster presentation at the European Alliance of Associations for Rheumatology (EULAR) 2026, being held June 3-6, 2026, in London, England.

Updated findings from the ATLAS open-label extension trial will highlight the long-term tolerability profile of AP01 (inhaled pirfenidone) among the cohort of patients with progressive pulmonary fibrosis at up to four years of treatment. See the EULAR online program for more details. The presentation will also be accessible on the company’s website.

EULAR 2026 Poster Presentation Details:

Title: Nebulized pirfenidone (AP01) for progressive pulmonary fibrosis in connective tissue disease-associated and other interstitial lung diseases: 4-year data from the ATLAS open label extension trial
Session: Poster View VIII, Saturday, June 6, 10:15 BST. Poster ID: POS1150
Speaker: Prof. Anna-Maria Hoffmann-Vold, Oslo University Hospital and University Hospital Zurich
Authors: Anna-Maria Hoffmann-Vold, Felix Woodhead, Nazia Chaudhuri, Deepthi Nair, Shailendra Menjoge, Hao Bao, Meredith Hart, Howard M. Lazarus, Craig Conoscenti

About Avalyn Pharma
Avalyn aims to transform the treatment paradigm for pulmonary fibrosis and other serious, rare respiratory diseases. The company is advancing optimized inhaled formulations of established antifibrotic medicines designed to deliver drug directly to the lungs, enhance local efficacy, and reduce systemic side effects. Avalyn’s AP01 program is an optimized inhaled formulation of pirfenidone currently being evaluated in MIST, a global Phase 2b clinical trial in patients with progressive pulmonary fibrosis (PPF). AP01 has indicated encouraging safety and clinical activity across Phase 1b and multi-year open-label extension trials, with long-term data supporting the potential to preserve lung function while improving tolerability relative to historical oral pirfenidone. Avalyn’s AP02 program is an optimized inhaled formulation of nintedanib currently being evaluated in AURA-IPF, a global Phase 2 clinical trial in patients with idiopathic pulmonary fibrosis (IPF). Avalyn is also advancing AP03, an inhaled fixed-dose combination of pirfenidone and nintedanib, designed to deliver multiple antifibrotic mechanisms through a single lung-targeted platform. By leveraging its proprietary drug-device approach and deep expertise in rare respiratory disease development, Avalyn aims to establish a new standard of care in pulmonary fibrosis through inhaled, lung-targeted therapies. For more information, please visit avalynpharma.com and follow the company on LinkedIn.

Investor Contact:
Cassie Saitow, Avalyn Pharma Inc.
Sr. Director, IR and Corporate Communications
ir@avalynpharma.com

Media Contact:
Kat Lippincott, Deerfield Group
kat.lippincott@deerfieldgroup.com
media@avalynpharma.com

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Avalyn (Nasdaq: AVLN) announce about AP01 at EULAR 2026?

Avalyn announced an upcoming EULAR 2026 poster with updated long-term tolerability data on AP01, inhaled pirfenidone, in progressive pulmonary fibrosis. According to Avalyn, the ATLAS open-label extension trial provides up to four years of treatment data for this inhaled therapy.

When and where is Avalyn's AP01 poster session at EULAR 2026?

Avalyn’s AP01 poster will be presented at EULAR 2026 in London on Saturday, June 6, 2026, at 10:15 BST. According to Avalyn, the session is part of Poster View VIII and the poster is identified as POS1150.

What is the focus of Avalyn's ATLAS trial data on AP01 for pulmonary fibrosis?

The ATLAS open-label extension trial focuses on the long-term tolerability profile of AP01 in progressive pulmonary fibrosis. According to Avalyn, updated findings cover patients treated for up to four years, including those with connective tissue disease-associated and other interstitial lung diseases.

How can investors access Avalyn's AP01 EULAR 2026 poster presentation?

Investors can access Avalyn’s AP01 EULAR 2026 poster presentation through the company’s website. According to Avalyn, additional logistical information, including session time and poster ID POS1150, is also available via the EULAR 2026 online program for attendees.

Which patients are included in Avalyn's AP01 ATLAS long-term data presented at EULAR 2026?

The AP01 ATLAS long-term data include patients with progressive pulmonary fibrosis, including connective tissue disease-associated and other interstitial lung diseases. According to Avalyn, these patients received nebulized pirfenidone (AP01) for up to four years in the open-label extension trial.